Ester Lovsin Barle, PhD, MScTox, ERT, Takeda - Qepler Summits And Conferences

Ester Lovsin Barle, PhD, MScTox, ERT

Head Product stewardship and Health
Basel, Switzerland
Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.

Ester Lovsin Barle, DVM, MSc, PhD, MScTox is the Head of Corporate Toxicology at the at Lonza and responsible for Health topics at the Corporate Lonza EHS.

Previously she has been the Head of Health Hazard Assessment in Novartis Global HSE & BCM. Her responsibilities include scientific development and cross-organizational implementation of health based exposure limits (HBEL), compiling global policy on occupational toxicology and patient safety related process in support of manufacturing in Lonza globally, as well as global implementation of safe handling of chemicals. She is leading the Lonza Global biosafety network. She received her PhD in veterinary sciences from University of Ljubljana, Slovenia and a second masters degree in toxicology and risk assessment from Medical University in Vienna.

Dr. Lovsin Barle is author/co-author of over 60 publications including peer-reviewed articles and book chapters. She is a member of several pharma industry and toxicological associations and boards and has served as the president of the Slovenian Society of toxicology. She lectures at several universities.

Privately she is a mother of two teenagers and is enthusiastic about balanced and healthy lifestyle which includes components of triathlon, mountain hiking and good food.

Related Sessions:

Highly Potent APIs
Summit 2019

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 20 Feb 2019
  • Berlin, DE
  • Pharma
Day 2: Thursday, 21 February 2019
WORKSHOP: How to identify high potency and high toxicity and what to do with it.
  • Data mining: Key information that determines toxicity and potency
  • Data interpretation: What should you ask yourself to interpret toxicity and potency correctly
  • Limit setting: How to set Health Based Exposure Limit
  • Using the limit: How to use the OEL and PDE in the risk assessments.
View Details

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 2: Thursday, 20 February 2020
WORKSHOP: Components of successful hazard communication
  • Where is the data
  • Best practices in communicating the hazards
  • Making decisions based on poor datasets
View Details